35771-65-4

Basic information

• Product Name: 5-(2-FURYL)-2 4-DIHYDRO-1 2 4-TRIAZOLE-&
• Synonyms: 5-(2-FURYL)-2 4-DIHYDRO-1 2 4-TRIAZOLE-&;5-furyl-1,2-dihydro-3H-1,2,4-triazole-3-thione;5-(2-Furanyl)-1,2-dihydro-3H-1,2,4-triazole-3-thione;1H-1,2,4-triazole-5-thiol, 3-(2-furanyl)-;3-(2-furyl)-1H-1,2,4-triazole-5-thiol;3-(furan-2-yl)-1H-1,2,4-triazole-5-thiol;5-(2-furyl)-1,2-dihydro-1,2,4-triazole-3-thione;5-furan-2-yl-1,2-dihydro-1,2,4-triazole-3-thione
• CAS NO: 35771-65-4
• Molecular Formula: C₆H₅N₃OS
• Molecular Weight: 167.1884
• EINECS: 252-719-6
• Product Categories: Building Blocks;Heterocyclic Building Blocks;Triazoles
• Mol File: 35771-65-4.mol
• Article Data: 6

Chemical Properties

• Melting Point: 277-278 °C(lit.)
• Boiling Point: 242.1°Cat760mmHg
• Flash Point: 100.2°C
• Appearance: /
• Density: 1.65g/cm³
• Vapor Pressure: 0.054mmHg at 25°C
• Refractive Index: 1.753
• CAS DataBase Reference: 5-(2-FURYL)-2 4-DIHYDRO-1 2 4-TRIAZOLE-&(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(2-FURYL)-2 4-DIHYDRO-1 2 4-TRIAZOLE-&(35771-65-4)
• EPA Substance Registry System: 5-(2-FURYL)-2 4-DIHYDRO-1 2 4-TRIAZOLE-&(35771-65-4)

Safety Data

• Safety Statements: 22-24/25
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 35771-65-4(Hazardous Substances Data)

Usage

General Description

5-(2-FURYL)-2,4-DIHYDRO-1,2,4-TRIAZOLE is a compound with a chemical structure containing a furan ring and a triazole ring. It is also known as FTR, and is used in the pharmaceutical industry as a potential therapeutic agent for various medical conditions. The compound has been found to exhibit anti-inflammatory, anti-cancer, and neuroprotective properties in preclinical studies. It is also being investigated for its potential in the treatment of diabetes and cardiovascular diseases. Additionally, 5-(2-FURYL)-2,4-DIHYDRO-1,2,4-TRIAZOLE has shown potential as an antimicrobial and antifungal agent, making it a promising candidate for the development of new antibiotics and antifungal drugs.

InChI:InChI=1/C6H5N3OS/c11-6-7-4-9(8-6)5-2-1-3-10-5/h1-4H,(H,8,11)

Upstream product

• 35771-64-3 1-(2-furoyl)-3-thiosemicarbazide 
• 3326-71-4 2-furoic acid hydrazide 
• 527-69-5 2-furancarbonyl chloride 
• 26172-44-1 2-furoylisothiocyanate 
• 1147550-11-5 ammonium thiocyanate 

Downstream Products

• 30452-55-2 (5-furan-2-yl-1H-[1,2,4]triazol-3-ylsulfanyl)-acetic acid 
• 30502-39-7 α-<5-(2-Furyl)-1,2,4-triazol-3-ylthio>acethydrazid 
• 34698-45-8 3-furan-2-yl-5-phenyl-thiazolo[2,3-c][1,2,4]triazole 

Relevant articles and documents

Triazole neuraminidase inhibitor as well as preparation method and application thereof

The invention relates to a triazole neuraminidase inhibitor and a preparation method and application thereof, and the inhibitor has the structure shown in the formula (I). The preparation method comprises: (1) forming a reaction system with substituted aniline and chloroacetyl chloride to obtain the intermediate of the formula (II). (2) A reaction system is formed by dissolving furanoyl chloride and thiosemicarbazone in an organic solvent to obtain the intermediate of formula (III). (3) (2) The obtained intermediate of formula (III) is dissolved in sodium hydroxide solution to form a reaction system to obtain the intermediate of formula (IV). (4) (3) The intermediate of formula (IV) obtained in Step (1) and the sodium hydroxide solution of formula (II) obtained in step (a) are dissolved in an organic solvent, and the reaction is post-treated to the inhibitor shown in formula (I). The compound disclosed by the invention is novel in structure, has good neuraminidase inhibitory activity and can be used for preparing a medicament for inhibiting neuraminidase activity.

1,2,4-TRIAZOLE, 1,3,4-OXADIAZOLE, AND 1,3,4-THIADIAZOLE DERIVATIVES AND THEIR ANTIMYCOBACTERIAL ACTIVITY

Disclosed herein are novel five membered heterocyclic compounds of Formula (I) wherein, X is S or SO2; n is 0, 1; m is1 or 2; Y is N, O or S; R2 independently represents H or alkyl or halo selected from -CI, -F; or -CF3, or -OH or-NH2 or - NO2; and R1 independently represents H or C1 to C5 straight or branched chain alkyl, alkenyl, alkynyl or a group -(CH2)5Br or pyrrolidine or - NHR' wherein R' is H or isopropyl or (II) or (III) which selectively act against dormant pathogenic tuberculi bacilli and exhibit antiproliferative activities and for treatment of a disease or disorder associated with GroEL1/GroEL2 activity. The invention relates to a process for preparation of novel five membered heterocyclic compounds of Formula I and to pharmaceutical compositions thereof.

5-Furan-2yl[1,3,4]oxadiazole-2-thiol, 5-furan-2yl-4h [1,2,4] triazole-3-thiol and their thiol-thione tautomerism

5-Furan-2-yl[1,3,4]oxadiazole-2-thiol (Ia) and 5-furan-2-yl-4H-[1,2,4]- triazole-3-thiol (Ib) were synthesized from furan-2-carboxylic acid hydrazide. Mannich bases and methyl derivatives were then prepared. The structures of the synthesized compounds were confirmed by elemental analyses, IR and 1H-NMR spectra. Their thiol-thione tautomeric equilibrium is described.